It’s been two years since the Inflation Reduction Act was passed, and while the law's Medicare-negotiated price cuts haven’t ...

Five years and nearly 50 episodes in, the CDC Foundation has given its “Contagious Conversations” podcast a makeover. | Five ...

Three years after launching Leqvio in the U.S., Novartis is still steadily advancing its blockbuster ambitions for the ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer. | A Merck & ...

The rightsizing at BioMarin continues to take its toll as CEO Alexander Hardy devises a new corporate strategy for the rare disease biotech. | The rightsizing at BioMarin continues to take its toll as ...

Active pharmaceutical ingredient maker Global Calcium has run afoul of FDA investigators on the heels of a recent inspection of the company’s factory in the Indian State of Tamil Nadu. | Following an ...

The latest vaccine push comes just a few months after Moderna kicked off another campaign encouraging uptake of its COVID shots. That initiative launched on March 15’s Long COVID Awareness Day, with a ...

Despite competing against several drugs that have been approved to fend off migraine headaches, AbbVie’s Ubrelvy (ubrogepant) —which is approved only to treat them—has carved out a significant nich | ...

Silence Therapeutics isn’t staying mum about the need for broader awareness of the risks associated with heightened levels of lipoprotein(a), or Lp(a). | Silence Therapeutics isn’t staying mum about ...

Novartis has formed a strategic collaboration with drug delivery specialist Lindy Biosciences to develop self-administered ...

As Stada Arzneimittel’s private equity owners continue to weigh their options around a potential sale or public offering, the ...

Eli Lilly has come up with a new way of supplying its popular weight-loss drug Zepbound that the company hopes could expand ...